The Latest Breaking News from Moderna

Scientists say there is no evidence to suggest that vaccinations are making COVID "stronger" and that mutations are a normal part of virus evolution.

Social media users shared a range of false claims this week

Biotech stocks can often be countercyclical, according to some market experts. We explore some biotech opportunities in this article.

A TORY MP has been accused of spreading “nonsense” about the Covid vaccine by a senior Conservative colleague.

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Afrigen is the linchpin of global project to use mRNA technology to empower low-resource countries to make their own vaccines against killer diseases from TB to HIV. What will it take to succeed?

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

Moderna has partnered with another drug company to produce a personalised vaccine against melanoma for people at risk of dying.